At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Delgocitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled, Single Site, Exploratory Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
In Brief
A Phase 2 clinical trial evaluating Delgocitinib cream and Delgocitinib cream vehicle for Frontal Fibrosing Alopecia. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions. The trial also investigated the clinical effect of delgocitinib cream on FFA compared to a placebo cream.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrontal Fibrosing Alopecia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartApr 2022
Primary CompletionFeb 2023
Study CompletionMay 2023
TodayJul 2026
First PostedApr 18, 2022
Enrollment StartApr 19, 2022
Primary CompletionFeb 13, 2023
Study CompletionMay 22, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago
Interventions
Delgocitinib creamdrug
Cream for topical application
Delgocitinib cream vehicledrug
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.